Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1487-1494

  Pajot, O ^a   Burdet, C ^b,c   Couffignal, C ^b,c   Massias, L ^b   Armand Lefevre, L ^b,c   Foucrier, A ^b   Da Silva, D ^b   Lasocki, S ^b   Laouenan C ^b,c   Mentec, H ^a   Mentre F ^b,c   Wolff, M ^b,c  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Antibiotics; ICUs; PD; PK; VAP

Indexed keywords

AMIKACIN; IMIPENEM; ANTIINFECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COUNT; BACTERIUM CULTURE; BLOOD SAMPLING; CLINICAL ARTICLE; COLONY FORMING UNIT; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY FUNCTION TEST; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SINGLE DRUG DOSE; VENTILATOR ASSOCIATED PNEUMONIA; VERY ELDERLY; BACTERIAL LOAD; DRUG COMBINATION; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84929733772     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku569     Document Type: Article

References (48)

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10; quiz 11-2.
3. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31:345-51.
4. Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51:1725-30.
5. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-9.
6. Zelenitsky SA, Harding GK, Sun S et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52:668-74.
7. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30:2145-56.
8. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58:916-29.
9. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
10. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. Jama 2003; 290:2588-98.
11. McCabe W, Jackson G. Gram-negative bacteremia: I. etiology and ecology. Arch Intern Med 1962; 110:847-55.
12. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63.
13. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-10.
14. Luna CM, Blanzaco D, Niederman MS et al. Resolution of ventilatorassociated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-82.
15. Pickering JW, Frampton CM,Walker RJ et al. Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care 2012; 16:R107.
16. White LO, Holt HA, Reeves DS et al. Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ ukneqasaa.win-uk.net. J Antimicrob Chemother 1997; 39:355-61.
17. Samson A, Lavielle M, Mentre F. The SAEMalgorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model. Stat Med 2007; 26:4860-75.
18. Couffignal C, Pajot O, Laouenan C et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Br J Clin Pharmacol 2014; 78:1022-34.
19. Burdet C, Pajot O, Couffignal C et al. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilatorassociated pneumonia. Eur J Clin Pharmacol 2014; doi:10.1007/ s00228-014-1766-y.
20. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_ files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf.
21. Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drugs 2007; 67:1027-52.
22. van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16 Suppl 3: S235-8.
23. Schentag JJ, Reitberg DP, Cumbo TJ. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Am J Med 1984; 77:34-42.
24. Schentag JJ, Smith IL, Swanson DJ et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77:43-50.
25. Team RC. A Language and Environment for Statistical Computing. 2013. http://www.r-project.org/.
26. Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12:77.
27. Therneau T, Atkinson B, Ripley B. Recursive Partitioning for Classification, Regression and Survival Trees. R package version 4.1-8. 2014. http://cran. r-project.org/package=rpart.
28. Vogelman B, Gudmundsson S, Leggett J et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158:831-47.
29. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38:931-6.
30. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27:10-22.
31. Manduru M, Mihm LB, White RL et al. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997; 41:2053-6.
32. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50:425-8.
33. Dulhunty JM, Roberts JA, Davis JS et al. Continuous infusion of β-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236-44.
34. Scaglione F, Esposito S, Leone S et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 2009; 34:394-400.
35. Belzberg H, Zhu J, Cornwell EE 3rd et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004; 56:111-7.
36. McKindley DS, Boucher BA, Hess MM et al. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996; 16:924-31.
37. Novelli A, Adembri C, Livi P et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44:539-49.
38. Sakka SG, Glauner AK, Bulitta JB et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51:3304-10.
39. Taccone FS, Laterre PF, Spapen H et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14:R53.
40. Kashuba AD, Nafziger AN, Drusano GL et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-9.
41. Cornwell EE 3rd, Belzberg H, Berne TV et al. Aminoglycoside levels in critically ill surgical patients: the implications of physiologic criteria of sepsis. South Med J 1997; 90:33-6.
42. Galvez R, Luengo C, Cornejo R et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011; 38:146-51.
43. Mahmoudi L, Mohammadpour AH, Ahmadi A et al. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 2013; 17:285-91.
44. de Montmollin E, Bouadma L, Gault N et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 2014; 40:998-1005.
45. Montravers P, Fagon JY, Chastre J et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147:38-44.
46. Kumar A, Safdar N, Kethireddy S et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/ meta-regression study. Crit Care Med 2010; 38:1651-64.
47. Torres A, De La Bellacasa JP, Xaubet A et al. Diagnostic Value of quantitative cultures of bronchoalveolar lavage and telescoping plugged catheters in mechanically ventilated patients with bacterial pneumonia. Am Rev Respir Dis 1989; 140:306-10.
48. Jamal J-A, Abdul-Aziz M-H, Lipman J et al. Defining antibiotic dosing in lung infections. Clin Pulm Med 2013; 20:121-8.